The Department of Infectious Diseases at Augusta University conducts Clinical Trials relating to a wide variety of pertinent infectious diseases. The following is a non-comprehensive list of currently active studies in the department. If you are interested in learning more about a specific study, please contact the study coordinator listed for the study and we would be more than happy to provide you will further details.

Official Title

Primary Investigator 

Study Coordinator


A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 Jose Vazquez Aprile Osborn Regeneron Pharmaceuticals
Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)  Jose Vazquez Aprile Osborn PTC Therapeutics
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive Candidasis (RESTORE) Jose Vazquez Aprile Osborn Cidara Therapeutics
NCT04340388 Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV   Jonell Poe Ryan Harris
Amber Ladak
Reva Crandall
Jacob Looney


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract  Andrew Chao Aprile Osborn Enanta Pharmceuticals
NCT04442737 A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain With an INI + TAF/FTC ARV Regimen Cheryl Newman Marti Farrough Janssen Scientific Affairs
NCT03059992 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Jose Vazquez Aprile Osborn  
  SARS CoV-2 shedding, sequence variation and immune responses in confirmed and suspected COVID-19 patients Jose Vazquez Aprile Osborn  
NCT04160468 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis (DISRUPT)  Jose Vazquez Aprile Osborn